Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans.
Ontology highlight
ABSTRACT: Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Timely administration of antibiotics approved for the treatment of anthrax disease may prevent associated morbidity and mortality. However, any delay in initiating antimicrobial therapy may result in increased mortality, as inhalational anthrax progresses rapidly to the toxemic phase of disease. An anthrax antitoxin, AVP-21D9, also known as Thravixa (fully human anthrax monoclonal antibody), is being developed as a therapeutic agent against anthrax toxemia. The efficacy of AVP-21D9 in B. anthracis-infected New Zealand White rabbits and in cynomolgus macaques was evaluated, and its safety and pharmacokinetics were assessed in healthy human volunteers. The estimated mean elimination half-life val
SUBMITTER: Malkevich NV
PROVIDER: S-EPMC4068543 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA